Download PDF
Horm Metab Res 2012; 44(11): 832-838
DOI: 10.1055/s-0032-1321832
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Prolactinoma: A Condition Associated with Hypoadiponectinemia

L. F. de Assunção Alves Rodrigues
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
S.M. S. Campos
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
P.A. C. Miranda
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
M. F. Bizzi
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
P. H. Sales do Amaral
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
A. V. Giannetti
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
,
A. Ribeiro-Oliveira
1   Laboratory of Endocrinology, Federal University of Minas Gerais, Minas Gerais, Brazil
› Author Affiliations
Further Information

Publication History

received 08 March 2012

accepted 25 June 2012

Publication Date:
30 July 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Prolactinomas are prolactin-secreting neoplasias accounting for 40% of the pituitary adenomas. Much is known about the effects of prolactinomas on the reproductive system, but few data are yet available regarding their induced changes on metabolism. This study was aimed at evaluating patients with prolactinomas for insulin resistance and adiponectinemia. Forty patients with prolactinoma were allocated to 2 different groups according to disease control: 20 with uncontrolled disease (UPRL) and 20 with controlled disease in the last 6 months (CPRL). Forty healthy individuals (CG) matched for age, sex, and body mass index were taken as controls. Patients with prolactinoma were compared both as a one group and according to disease control with CG. All subjects were evaluated for waist/hip ratio (WHR), blood pressure, lipid profile, fasting glucose, homeostasis assessment model of insulin resistance (HOMAIR), and adiponectin. Patients with prolactinomas (UPRL+CPRL) showed higher insulin (p<0.05) and HOMAIR (p<0.05), alongside with lower adiponectin levels (p<0.01) than matched controls. When UPRL was compared to CPRL and CG, UPRL was disclosed as a subgroup of significant altered metabolic profile as related to WHR (p<0.01 for comparisons), high-density lipoprotein cholesterol (p<0.05 for comparisons), triglycerides (p<0.05 for comparisons), HOMAIR (p<0.05 and p<0.01, respectively), and adiponectin (p<0.01 for comparisons). All these metabolic abnormalities, except hypoadiponectinemia (p<0.01), were not observed in CPRL. These data suggest that prolactinomas are associated with hypoadiponectinemia, which is further exacerbated in uncontrolled patients when insulin resistance is also prominent.

Key words

adiponectin - hyperlipidemia - HOMAIR - insulin resistance - prolactin
 

  • References

  • 1 Freeman M, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631
    CrossrefPubMedGoogle Scholar
  • 2 Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
    CrossrefPubMedGoogle Scholar
  • 3 Reis FM, Ribeiro-de-Oliveira A, Guerra RM, Reis AM, Coimbra CC. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sci 1996; 58: 155-161
    PubMedGoogle Scholar
  • 4 Schmid C, Goede D, Hauser R, Brändle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Weekly 2006; 136: 254-258
    PubMedGoogle Scholar
  • 5 Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003; 149: 187-193
    CrossrefPubMedGoogle Scholar
  • 6 Reuwer AQ, van Zaane B, van Wissen M, van Zanten AP, Twickler MT, Gerdes VE. Prolactin is involved in the systemic inflammatory response in myocardial infarction. Horm Metab Res 2011; 43: 62-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19: 800-805
    CrossrefPubMedGoogle Scholar
  • 8 Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19: 667-670
    CrossrefPubMedGoogle Scholar
  • 9 Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207
    CrossrefPubMedGoogle Scholar
  • 10 Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107
    CrossrefPubMedGoogle Scholar
  • 11 Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002; 367: 677-685
    CrossrefPubMedGoogle Scholar
  • 12 Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751
    CrossrefPubMedGoogle Scholar
  • 13 Fruebis J, Tsao T, Javorschi S, Ebbets-Reed D, Erickson M, Yen F, Bihain B, Lodish H. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98: 2005-2010
    CrossrefPubMedGoogle Scholar
  • 14 Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn B, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295
    CrossrefPubMedGoogle Scholar
  • 15 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R, Tataranni P. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935
    CrossrefPubMedGoogle Scholar
  • 16 Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly P, Kopchick J, Ormandy C, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 2005; 331: 1120-1126
    CrossrefPubMedGoogle Scholar
  • 17 Asai-Sato M, Okamoto M, Endo M, Yoshida H, Murase M, Ikeda M, Sakakibara H, Takahashi T, Hirahara F. Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006; 53: 555-562
    CrossrefPubMedGoogle Scholar
  • 18 Fuglsang J, Skjaerbaek C, Frystyk J, Flyvbjerg A, Ovesen P. A longitudinal study of serum adiponectin during normal pregnancy. BJOG 2006; 113: 110-113
    PubMedGoogle Scholar
  • 19 Geloneze B, Repetto E, Geloneze S, Tambascia M, Ermetice M. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006; 72: 219-220
    CrossrefPubMedGoogle Scholar
  • 20 Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
    CrossrefPubMedGoogle Scholar
  • 21 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194
    CrossrefPubMedGoogle Scholar
  • 22 Kyriazi E, Tsiotra PC, Boutati E, Ikonomidis I, Fountoulaki K, Maratou E, Lekakis J, Dimitriadis G, Kremastinos DT, Raptis SA. Effects of adiponectin in TNF-α, IL-6, and IL-10 cytokine production from coronary artery disease macrophages. Horm Metab Res 2011; 43: 537-544
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients?. Clin Endocrinol (Oxf) 1999; 50: 271
    PubMedGoogle Scholar
  • 24 Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejìas M, Hernàndez L. Antipsychotic drugs and obesity: is prolactin involved?. Can J Psychiatry 2001; 46: 829-834
    PubMedGoogle Scholar
  • 25 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48: 547-553
    CrossrefPubMedGoogle Scholar
  • 26 Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003; 88: 1804-1808
    CrossrefPubMedGoogle Scholar
  • 27 Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009; 12: 330-334
    CrossrefPubMedGoogle Scholar
  • 28 Galsgaard ED, Nielsen JH, Møldrup A. Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells. Prolactin and growth hormone activate one of the rat prlr gene promoters via STAT5a and STAT5b. J Biol Chem 1999; 274: 18686-18692
    CrossrefPubMedGoogle Scholar
  • 29 Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985; 28: 138-142
    CrossrefPubMedGoogle Scholar
  • 30 Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-794
    CrossrefPubMedGoogle Scholar
  • 31 Ribeiro-de-Oliveira A, Guerra RM, Fóscolo RB, Marubayashi U, Reis AM, Coimbra CC. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol 1999; 162: 237-242
    CrossrefPubMedGoogle Scholar
  • 32 Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003; 52: 268-276
    CrossrefPubMedGoogle Scholar
  • 33 Shen W, Wang Z, Punyanita M, Lei J, Sinav A, Kral JG, Imielinska C, Ross R, Heymsfield SB. Adipose tissue quantification by imaging methods: a proposed classification. Obes Res 2003; 11: 5-16
    CrossrefPubMedGoogle Scholar
  • 34 Hoenig MR. MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort. Vasc Health Risk Manag 2010; 6: 629-633
    PubMedGoogle Scholar
  • 35 Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007; 56: 804-808
    CrossrefPubMedGoogle Scholar